Publications by authors named "Yuichiro Kashiwamura"
Int J Hematol
December 2022
Article Synopsis
- This study compared the effectiveness and safety of a filgrastim biosimilar (F-BS) to the original filgrastim in treating malignant lymphoma in 78 patients undergoing CHASE (± R) or DeVIC (± R) therapies.
- Results showed that both groups had similar median doses of treatment, days to neutrophil recovery, and incidences of febrile neutropenia (FN), indicating comparable efficacy and safety between F-BS and original filgrastim.
- Additionally, using F-BS resulted in lower medical costs, saving about $170.22 per course of CHASE (± R) therapy.
